Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Solid Tumors · Pancreatic Cancer · MREO

MEREO BIOPHARMA GROUP

Mereo BioPharma Group plc

MEREO BIOPHARMA GROUP clinical programs — 47 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
Status
Public
HQ
4TH FLOOR, ONE, LONDON, USA
Employees
4
Programs
47
Drugs
22
Patents
18
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

MEREO BIOPHARMA GROUP projects

47 ClinicalTrials.gov programs sponsored by MEREO BIOPHARMA GROUP.

MEREO BIOPHARMA GROUP has 47 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

47 programs

Clinical programs

  1. Setrusumab

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 3 mab active

    2 trials

  2. Active treatment with a high dose of BGS649

    Mereo BioPharma Group plc

    Endometriosis

    phase 2 small molecule completed

    1 trial

  3. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  4. Alvelestat (MPH966)

    Mereo BioPharma Group plc

    Alpha-1 Antitrypsin Deficiency (AATD)

    phase 2 small molecule completed

    1 trial

  5. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  6. BCT197

    Mereo BioPharma Group plc

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  7. BCT197 Part A

    Mereo BioPharma Group plc

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  8. BGS649

    Mereo BioPharma Group plc

    Hypogonadotropic Hypogonadism

    phase 2 small molecule completed

    2 trials

  9. BGS649

    Mereo BioPharma Group plc

    Pelvic Pain Associated With Refractory Endometriosis

    phase 2 small molecule terminated

    1 trial

  10. BPS804

    Mereo BioPharma Group plc

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  11. BPS804

    Mereo BioPharma Group plc

    Hypophosphatasia

    phase 2 small molecule completed

    1 trial

  12. BPS804

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 2 small molecule terminated

    1 trial

  13. BPS804 20mg/Kg

    Mereo BioPharma Group plc

    Osteopenia

    phase 2 small molecule completed

    1 trial

  14. Demcizumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 2 small molecule completed

    2 trials

  15. Etigilimab

    Mereo BioPharma Group plc

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  16. Investigational new drug company code: BGS649

    Mereo BioPharma Group plc

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  17. MPH966

    Mereo BioPharma Group plc

    Hematologic Malignancy

    phase 2 small molecule terminated

    1 trial

  18. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  19. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  20. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  21. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  22. Placebo Oral Tablet

    Mereo BioPharma Group plc

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  23. setrusumab

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta, Type I

    phase 2 small molecule completed

    1 trial

  24. BCT197

    Mereo BioPharma Group plc

    Interaction

    phase 1 small molecule completed

    2 trials

  25. Demcizumab

    Mereo BioPharma Group plc

    Primary Peritoneal Carcinoma

    phase 1 small molecule terminated

    1 trial

  26. Demcizumab

    Mereo BioPharma Group plc

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  27. Demcizumab

    Mereo BioPharma Group plc

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  28. Docetaxel

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  29. OMP-131R10

    Mereo BioPharma Group plc

    Advanced Relapsed Tumors

    phase 1 small molecule completed

    1 trial

  30. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  31. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  32. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  33. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  34. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  35. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  36. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  37. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  38. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Lymphoid Malignancies

    phase 1 small molecule completed

    1 trial

  39. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  40. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  41. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  42. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  43. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  44. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  45. Vantictumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  46. Vantictumab combined with paclitaxel

    Mereo BioPharma Group plc

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  47. brontictuzumab

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does MEREO BIOPHARMA GROUP have?

47 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.